Peter Lynch · Growth at a reasonable price (GARP)
Is Regeneron Pharmaceuticals, Inc. (REGN) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria, growth too low or price too high.
24/100
Ne correspond pas
3/6 critères validés
Les critères de Peter Lynch, appliqués à REGN
PEG ≤ 1.0
clé-
EPS CAGR ≥ 15%
clé-13.3%
Revenue CAGR ≥ 10%
-2.8%
Net margin > 0
29.6%
Comment REGN se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$75.69B
PER (TTM)
16.4x
ROIC (TTM)
8.53%
Marge brute
84.55%
Autres analyses Peter Lynch
Questions fréquentes
What is REGN's Peter Lynch fit score?
REGN scores 24/100 on our Peter Lynch fit engine. Does not fit Lynch's GARP criteria, growth too low or price too high.
Does Peter Lynch actually own REGN?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends REGN.
How often is this score updated?
REGN's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande REGN personnellement.
